

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7441599

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST
CONVEYING PARTY DATA	
Name	Execution Date
HANSA BIOPHARMA AB	07/18/2022
RECEIVING PARTY DATA	
Name:	NQ PROJECT BRIDGETON, L.P.
Street Address:	4208 SIX FORKS ROAD
Internal Address:	SUITE 920
City:	RALEIGH
State/Country:	NORTH CAROLINA
Postal Code:	27609
PROPERTY NUMBERS Total: 3	
Property Type	Number
Patent Number:	8133483
Patent Number:	10973889
Application Number:	17191634
CORRESPONDENCE DATA	
Fax Number:	(919)536-6201
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	9195366200
Email:	jennifer.snead@btlaw.com
Correspondent Name:	BARNES & THORNBURG LLP
Address Line 1:	4208 SIX FORKS ROAD
Address Line 2:	SUITE 1010
Address Line 4:	RALEIGH, NORTH CAROLINA 27609
ATTORNEY DOCKET NUMBER:	82100.21
NAME OF SUBMITTER:	BASHIR M. ALI, REG. NO. 47939
SIGNATURE:	/Bashir Ali/
DATE SIGNED:	07/20/2022
Total Attachments: 4	
source=NovaQuest - Hansa - Patent Security Agreement (fully executed)#page1.tif	
source=NovaQuest - Hansa - Patent Security Agreement (fully executed)#page2.tif	

source=NovaQuest - Hansa - Patent Security Agreement (fully executed)#page3.tif

source=NovaQuest - Hansa - Patent Security Agreement (fully executed)#page4.tif

Patent Security Agreement

THIS PATENT SECURITY AGREEMENT (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “*Patent Security Agreement*”) is made effective as of July 18, 2022, by and from Hansa Biopharma AB, a Swedish aktiebolag having an address of P.O. Box 785, SE-220 07, Lund, Sweden (the “*Grantor*”), to and in favor of NQ Project Bridgeton, L.P., a Delaware limited partnership (the “*Grantee*”).

WHEREAS, the Grantor and the Grantee have entered into a Funding Agreement dated as of July 18, 2022 (as may be amended, restated, supplemented or otherwise modified from time to time, the “*Funding Agreement*”).

WHEREAS, the Grantor has entered into a Security Agreement in favor of the Grantee dated as of July 18, 2022 (as may be amended, restated, supplemented or otherwise modified from time to time, the “*Security Agreement*”).

WHEREAS, the Grantor owns the patents listed on Schedule A attached hereto (the “*Patents*”), which Patents are pending or registered with the United States Patent and Trademark Office.

WHEREAS, this Patent Security Agreement has been executed in conjunction with the security interest granted under the Security Agreement to the Grantee. In the event that any provisions of this Patent Security Agreement are deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall govern.

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, it is hereby agreed that:

1. Definitions. All capitalized terms not defined herein shall have the respective meaning given to them in the Funding Agreement or the Security Agreement.

2. The Security Interest.

(a) This Patent Security Agreement is made to secure the prompt and complete payment and performance of all the Secured Obligations. Upon the occurrence of the Termination Date (as defined in the Security Agreement), the Grantee shall promptly, upon such satisfaction, execute, acknowledge, and deliver to the Grantor all reasonably requested instruments in writing releasing the security interest in the Patents acquired under the Security Agreement and this Patent Security Agreement.

(b) The Grantor hereby pledges and grants to the Grantee a security interest in all of the Grantor’s right, title and interest, wherever located and whether now owned or hereafter acquired, in and to (i) any and all patents and patent applications, including those listed on Schedule A hereto; (ii) all inventions and improvements described and claimed therein; (iii) all reissues, divisions, continuations, renewals, extensions, and continuations-in-part thereof; (iv) all income, royalties, damages, claims, and payments now or hereafter due or payable under and with


respect thereto, including, without limitation, damages and payments for past and future infringements thereof; (v) all rights to sue for past, present, and future infringements thereof; and (vi) all rights corresponding to any of the foregoing throughout the world.

3. Governing Law. **THIS PATENT SECURITY AGREEMENT SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAW OF THE STATE OF NEW YORK.**

4. Recordation. The Grantor hereby authorizes and requests that the Commissioner of Patents and Trademarks record this Patent Security Agreement.

IN WITNESS WHEREOF, the Grantor has executed this Patent Security Agreement effective as of the date first written above.

HANSA BIOPHARMA AB


By:  _____
DocuSigned by: C4DA83D87881423...

Name: Sören Tulstrup

Title: President & CEO


NQ Project Bridgeton, L.P.

By: NQ POF V GP, Ltd, its general partner

By:  _____
DocuSigned by: 1645C3388F43E...


Name: John L. Bradley, Jr.

Title: Director

By:  _____
DocuSigned by: BC577DD889CB4F8...

Name: Donato Spota

Title: CFO

By:  _____
DocuSigned by: F55D8C3889CF44E...

Name: Ferdinand winter

Title: General Counsel

Schedule A

Patents

Title	Patent No. / Publication No.	Date Issued	Application No.	Date Filed
Method of Treating or Preventing a Disease or Condition Mediated by Pathogenic IGG Antibodies (based on PCT Publication No. WO2006/131347)	US patent 8,133,483B2	3/13/2012	11/921,770	06/08/2006
Method for Improving the Benefit of Organ Transplant (based on PCT Publication No. WO2016/012285)	US Patent No.10,973,889B2	4/13/2021	15/328,879	7/10/2015
Method (based on PCT Publication No. WO2006/131347)	US Patent Publication No. 2021/0260173		17/191,634	03/03/2021